432 related articles for article (PubMed ID: 24920795)
1. Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.
Guichelaar T; Hoeboer J; Widjojoatmodjo MN; Reemers SS; van Els CA; Otten R; van Remmerden Y; Boes J; Luytjes W
J Virol; 2014 Sep; 88(17):9744-50. PubMed ID: 24920795
[TBL] [Abstract][Full Text] [Related]
2. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein.
Schepens B; Sedeyn K; Vande Ginste L; De Baets S; Schotsaert M; Roose K; Houspie L; Van Ranst M; Gilbert B; van Rooijen N; Fiers W; Piedra P; Saelens X
EMBO Mol Med; 2014 Nov; 6(11):1436-54. PubMed ID: 25298406
[TBL] [Abstract][Full Text] [Related]
3. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
4. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
5. Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine.
Tien Nguyen D; Boes J; van Amerongen G; van Remmerden Y; Yüksel S; Guichelaar T; Osterhaus AD; de Swart RL
Hum Vaccin Immunother; 2013 Dec; 9(12):2578-83. PubMed ID: 23955280
[TBL] [Abstract][Full Text] [Related]
6. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
[TBL] [Abstract][Full Text] [Related]
7. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
[TBL] [Abstract][Full Text] [Related]
8. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque.
Jenkins T; Wang R; Harder O; Xue M; Chen P; Corry J; Walker C; Teng M; Mejias A; Ramilo O; Niewiesk S; Li J; Peeples ME
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177201
[TBL] [Abstract][Full Text] [Related]
9. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
[TBL] [Abstract][Full Text] [Related]
10. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
Taylor G; Thom M; Capone S; Pierantoni A; Guzman E; Herbert R; Scarselli E; Napolitano F; Giuliani A; Folgori A; Colloca S; Cortese R; Nicosia A; Vitelli A
Sci Transl Med; 2015 Aug; 7(300):300ra127. PubMed ID: 26268314
[TBL] [Abstract][Full Text] [Related]
12. A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.
Díaz FE; Guerra-Maupome M; McDonald PO; Rivera-Pérez D; Kalergis AM; McGill JL
Front Immunol; 2021; 12():664212. PubMed ID: 33981309
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
14. Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.
Farrag MA; Amer HM; Öhlschläger P; Hamad ME; Almajhdi FN
Hum Vaccin Immunother; 2017 Jul; 13(7):1586-1597. PubMed ID: 28272978
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
16. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
19. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.
Mok H; Lee S; Utley TJ; Shepherd BE; Polosukhin VV; Collier ML; Davis NL; Johnston RE; Crowe JE
J Virol; 2007 Dec; 81(24):13710-22. PubMed ID: 17928349
[TBL] [Abstract][Full Text] [Related]
20. Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
Blodörn K; Hägglund S; Fix J; Dubuquoy C; Makabi-Panzu B; Thom M; Karlsson P; Roque JL; Karlstam E; Pringle J; Eléouët JF; Riffault S; Taylor G; Valarcher JF
PLoS One; 2014; 9(6):e100392. PubMed ID: 24945377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
